Neurocrine Biosciences (NBIX) Non-Current Assets (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Non-Current Assets of $3.7 billion for Q2 2026, up 73.83% year-over-year from $2.1 billion in Q2 2025, and up 50.67% on a QoQ basis from $2.5 billion in Q1 2026.
Neurocrine Biosciences (NBIX) Non-Current Assets (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Non-Current Assets for 17 years, with the latest figure at $3.7 billion in Q2 2026.
- Non-Current Assets for Q2 2026 came in at $3.7 billion, up 73.83% year-over-year; the trailing twelve-month figure through Jun 2026 was $10.4 billion (up 32.7% YoY), and the FY2025 annual result was $2.1 billion, up 5.76% from the prior year.
- Non-Current Assets grew to $3.7 billion in Q2 2026, from $2.5 billion in the prior quarter.
- Over five years, Non-Current Assets peaked at $3.7 billion in Q2 2026 and troughed at $915.2 million in Q4 2022.
- A 5-year average of $1.7 billion and a median of $1.7 billion in 2023 frame the typical range for Non-Current Assets.
- The widest annual swing landed in 2023, when Non-Current Assets retreated 17.7%; it then jumped 80.52% in 2024.
- A 5-year view of Non-Current Assets shows it stood at $915.2 million in 2022, then surged by 79.68% to $1.6 billion in 2023, then advanced by 21.26% to $2.0 billion in 2024, then rose by 5.76% to $2.1 billion in 2025, then jumped by 76.48% to $3.7 billion in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $3.7 billion in Q2 2026, $2.5 billion in Q1 2026, and $2.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | 2.87 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.72 Bn |
| Mar 31, 2026 | 2.47 Bn |
| Dec 31, 2025 | 2.11 Bn |
| Sep 30, 2025 | 2.11 Bn |
| Jun 30, 2025 | 2.14 Bn |
| Mar 31, 2025 | 2.05 Bn |
| Dec 31, 2024 | 1.99 Bn |
| Sep 30, 2024 | 1.66 Bn |
| Jun 30, 2024 | 1.64 Bn |
| Mar 31, 2024 | 1.67 Bn |
| Dec 31, 2023 | 1.64 Bn |
| Sep 30, 2023 | 1.20 Bn |
| Jun 30, 2023 | 1.12 Bn |
| Mar 31, 2023 | 927.00 Mn |
| Dec 31, 2022 | 915.20 Mn |
| Sep 30, 2022 | 937.90 Mn |
| Jun 30, 2022 | 986.40 Mn |
| Mar 31, 2022 | 1.13 Bn |
| Dec 31, 2021 | 1.10 Bn |
| Sep 30, 2021 | 1.01 Bn |